Cypex - in vitro drug metabolism systems
Cypex - in vitro drug metabolism systems
Cypex - in vitro drug metabolism systemsproducts and services

Cypex - in vitro drug metabolism systemsabout us

Cypex - in vitro drug metabolism systemslatest news

Cypex - in vitro drug metabolism systemsdata sheets
Cypex - in vitro drug metabolism systemspublications
Cypex - in vitro drug metabolism systemsfrequently asked questions
Cypex - in vitro drug metabolism systemsassays
Cypex - in vitro drug metabolism systemscontact us
linksCypex - in vitro drug metabolism systems
Cypex - in vitro drug metabolism systems
Follow us:   RSS Feed icon   LinkedIn logo
bio-dundee logoscottish enterprise biotech

Downloadable pdf versions of data obtained using Cypex products presented by Cypex and other organisations can be obtained here

Heterologously expressed human cytochrome P450 enzymes as a tool for understanding and predicting drug metabolism.
Urban, G., Gasser, R., Pritchard, M., Bandera, M. & Friedberg, T.
Exp. Toxic. Pathol. 48 Suppl II pp.409-414 (1996)

Coexpression of a human P450 (CYP3A4) and P450 reductase generates a highly functional monooxygenase system in Escherichia coli.
Blake, J.A.R., Pritchard, M., Ding, S., Smith, G.C.M., Burchell, B., Wolf, C. R. & Friedberg, T.
FEBS Letters 397 pp.210-214 (1996)

A general strategy for the expression of recombinant human cytochrome P450s in Escherichia coli using bacterial signal peptides: expression of CYP3A4, CYP2A6, and CYP2E1.
Pritchard, M.P., Ossetian, R., Li, D.N., Henderson, C.J., Burchell, B., Wolf, C.R. & Friedberg, T.
Arch. Biochem. Biophys. 345 (2) pp.342-354 (1997)

Functional co-expression of CYP2D6 and human NADPH-cytochrome P450 reductase in Escherichia coli.
Pritchard, M.P., Glancey, M.J., Blake, J.A.R., Gilham, D.E., Burchell, B., Wolf, C.R. & Friedberg, T.
Pharmacogenetics 8 pp.33-42 (1998)

Effects of cytochrome b5 on CYP3A4 activity and stability in vivo.
Voice, M.W., Zhang, Y., Wolf, C.R., Burchell, B. & Friedberg, T.
Arch. Biochem. Biophys. 366 (1) pp.116-124 (1999)

Rapid Characterisation of the major drug-metabolising human hepatic cytochrome P-450 enzymes expressed in Escherichia coli.
McGinnity, D.F., Griffin, S.J., Moody, G.C., Voice, M., Hanlon, S., Friedberg, T. & Riley, R. J.
Drug Metab. Dispos. 27 (9) pp.1017-1023 (1999)

In vivo and in vitro recombinant DNA technology as a powerful tool in drug development.
Friedberg, T., Henderson, C.J., Pritchard, M.P. & Wolf, C.R.
Handbook of Drug Metabolism, Chapter 13, pp.322-362 Ed T.F. Wolf, Pub. Marcel Dekker, Inc. (1999)

Automated definition of the enzymology of drug oxidation by the major human drug metabolising cytochrome P450s.
McGinnity, D.F., Parker, A.J., Soars, M. & Riley, R.J.
Drug Metab. Dispos. 28 (11) pp.1327-1334 (2000)

Amino acid 305 determines catalytic center accessibility in CYP3A4.
Fowler, S.M., Riley, R.J., Pritchard, M.P., Sutcliffe, M.J., Friedberg, T. & Wolf, C.R.
Biochemistry 39 (15) pp.4406-4414 (2000)

A method for the simultaneous evaluation of the activities of seven major human drug-metabolising cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chroimatography tandem mass spectrometry.
Dierks, E.A., Stams, K.R., Lim, H-K., Cornelius, G., Zhang, H. & Ball, S.E.
Drug Metab. Dispos. 29 (1) pp.23-29 (2001)

Predicting drug pharmacokinetics in humans from in vitro metabolism studies.
McGinnity, D. F. & Riley, R. J.
Biochem. Soc. Trans. 29 pp. 135-139 (2001)


The following are made under licence from BTG International Ltd (AU730155, EP0914446, US6566108 and other patents pending): all recombinant cytochrome P450 products; 4'-hydroxydiclofenac; 6a-hydroxypaclitaxel.

United States Patent Nos. 5,420,027 or 5,240,831, Great Britain Patent No. 2266719 and other patents pending.

Designed and created by Rob Cook at Limehouse Design